西洛他唑对严重肢体缺血患者膝下动脉球囊成形术后疗效的随机对照试验
CABBAGE试验为多中心前瞻性随机开放标签盲终点研究,纳入53例严重肢体缺血患者,比较西洛他唑联合阿司匹林与单用阿司匹林在膝下动脉球囊成形术后的效果。结果显示两组3个月造影再狭窄率分别为82%和81%,无显著差异(P=0.91),主要不良肢体事件率亦无显著差异。
要点
- 西洛他唑未降低严重肢体缺血患者膝下动脉球囊成形术后3个月造影再狭窄率。
- 两组主要不良肢体事件率分别为11%和8%,无显著差异(P=0.73)。
- 围手术期并发症、大截肢、全因死亡及出血事件等次要终点均无显著差异。
核心结论
- 西洛他唑未能减少严重肢体缺血患者膝下动脉球囊成形术后3个月造影再狭窄。
研究设计与样本
- 多中心、前瞻性、随机、开放标签、盲终点研究,由独立血管造影核心实验室裁定。
- 西洛他唑联合阿司匹林组2例和单用阿司匹林组1例因未对膝下动脉狭窄病变行血管成形术而被排除分析。
- 最终西洛他唑联合阿司匹林组25例患者38条血管和单用阿司匹林组同等数量病例纳入分析。
主要发现
- 3个月再狭窄率在西洛他唑联合阿司匹林组为82%,单用阿司匹林组为81%,无显著差异(P=0.91)。
- 主要不良肢体事件率在西洛他唑联合阿司匹林组为11%,单用阿司匹林组为8%(P=0.73)。
- 任何次要终点均未观察到显著差异。
关键数值与推荐
- 主要终点为3个月造影再狭窄。
- 主要不良肢体事件定义为需要任何再次干预或大截肢。
- 主要次要终点包括围手术期并发症、大截肢、全因死亡和出血事件。
临床怎么用
- 对于严重肢体缺血患者膝下动脉球囊成形术后,西洛他唑联合阿司匹林未显示优于单用阿司匹林的减少再狭窄效果。
- 临床决策应基于患者个体情况,不应仅期望西洛他唑降低再狭窄而常规联合使用。
局限性
- 样本量较小,最终仅25例患者38条血管纳入分析。
- 随访时间短,仅评估3个月造影再狭窄。
- 开放标签设计可能引入偏倚,尽管采用盲终点和独立核心实验室裁定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal medical therapy after endovascular therapy in patients with critical limb ischemia (CLI) remains unclear. Therefore, we investigated whether cilostazol reduce restenosis after balloon angioplasty for infrapopliteal lesions in CLI patients. METHODS: This study was performed as a multicenter, prospective, randomized, open-label, blinded-end point study with independent angiographic core laboratory adjudication. Sixty patients were eligible and 53 patients were enrolled and allocated. The primary end point was 3-month angiographic restenosis. The main secondary end points included major adverse limb event (MALE defined as requirement of any reintervention or major amputation), perioperative complications, major amputation, all-cause death, and hemorrhagic events. RESULTS: A total of 53 patients were randomized and all received their allocated intervention. Two patients in the cilostazol plus aspirin group and 1 in the aspirin group did not undergo any angioplasty for infrapopliteal stenotic lesions, and therefore were excluded from analysis. Finally, 38 vessels in 25 patients in the cilostazol plus aspirin group and as many cases in the aspirin group were included in the analysis. There were no significant differences in baseline characteristics between the 2 groups. The 3-month restenosis rate was 82% in the cilostazol + aspirin group and 81% in the aspirin group, with no significant difference (P = 0.91). The MALE rate was 11% in the cilostazol plus aspirin group and 8% in the aspirin group (P = 0.73). In addition, no significant difference was observed in any secondary points. CONCLUSIONS: Cilostazol did not reduce 3-month angiographic restenosis after balloon angioplasty for below-the-knee lesion in CLI patients.
引用
- Soga Y, Takahara M, Iida O, et al. Efficacy of CilostAzol for Below-the-Knee Artery Disease after Balloon AnGioplasty in PatiEnts with Severe Limb Ischemia (CABBAGE Trial). Ann Vasc Surg. 2017. PMID: 28600024. doi:10.1016/j.avsg.2017.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。